THE ACETYLCHOLINESTERASE OXIME REACTIVATOR HI-6 IN MAN: PHARMOCOKINETICS AND TOLERABILITY IN COMBINATION WITH ATROPINE

PDF

Authors
  1. Clement, G.J.
  2. Bailey, D.G.
  3. Madill, H.D.
  4. Tran, L.T.
  5. Spence, D.
Corporate Authors
Defence Research Establishment Suffield, Ralston ALTA (CAN)
Abstract
In a double-blind, placebo-controlled, single-dose ascending pharmacokinetics and tolerance study, we evaluated the bispyridinium oxime HI-6 dichloride monohydrate (62.5, 125, 250, and 500 mg), administered intramuscularly with atropine sulphate, 2 mg, in 24 healthy male volunteers. Blood pressure, heart rate, respiratory rate, electrocardiographic parameters, mental acuity, and vision were not altered. Adverse events and changes in serum, urine, and semen labortaory tests were mild. The pharamacokinetics, safety, and apparent efficacy of HI-6 suggest it may be a superior oxime antidote against nerve agent poisoning.
Report Number
DRES-RP-95-0632 — Reprint
Date of publication
03 Jan 1995
Number of Pages
11
Reprinted from
Biopharmaceutics and Drug Disposition, vol 16, 1995, p 415-425
DSTKIM No
96-02438
CANDIS No
180692
Format(s):
Document Image stored on Optical Disk;Hardcopy

Permanent link

Document 1 of 1

Date modified: